229 related articles for article (PubMed ID: 26772175)
1. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
2. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.
Goodwin JS; Jaramillo E; Yang L; Kuo YF; Tan A
PLoS One; 2014; 9(9):e107352. PubMed ID: 25208250
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
4. The cost implications of prostate cancer screening in the Medicare population.
Ma X; Wang R; Long JB; Ross JS; Soulos PR; Yu JB; Makarov DV; Gold HT; Gross CP
Cancer; 2014 Jan; 120(1):96-102. PubMed ID: 24122801
[TBL] [Abstract][Full Text] [Related]
5. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
[TBL] [Abstract][Full Text] [Related]
6. New approaches to measuring the comprehensiveness of primary care physicians.
O'Malley AS; Rich EC; Shang L; Rose T; Ghosh A; Poznyak D; Peikes D
Health Serv Res; 2019 Apr; 54(2):356-366. PubMed ID: 30613955
[TBL] [Abstract][Full Text] [Related]
7. Primary Care Physicians Beliefs about Prostate-Specific Antigen Evidence Uncertainty, Screening Efficacy, and Test Use.
Ross LE; Hall IJ; Howard DL; Rim SH; Richardson LC
J Natl Med Assoc; 2018 Oct; 110(5):491-500. PubMed ID: 30129508
[TBL] [Abstract][Full Text] [Related]
8. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.
Bynum J; Song Y; Fisher E
J Am Geriatr Soc; 2010 Apr; 58(4):674-80. PubMed ID: 20345867
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
Etzioni R; Berry KM; Legler JM; Shaw P
Urology; 2002 Feb; 59(2):251-5. PubMed ID: 11834397
[TBL] [Abstract][Full Text] [Related]
10. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
11. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database.
Cole AP; Jiang W; Lipsitz SR; Learn PA; Sun M; Choueiri TK; Nguyen PL; Kibel AS; Menon M; Sammon JD; Koehlmoos T; Haider A; Trinh QD
J Urol; 2017 Dec; 198(6):1295-1300. PubMed ID: 28716650
[TBL] [Abstract][Full Text] [Related]
12. Discussions about prostate cancer screening between U.S. primary care physicians and their patients.
Hall IJ; Taylor YJ; Ross LE; Richardson LC; Richards TB; Rim SH
J Gen Intern Med; 2011 Oct; 26(10):1098-104. PubMed ID: 21416405
[TBL] [Abstract][Full Text] [Related]
13. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
14. Cost implications of PSA screening differ by age.
Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
[TBL] [Abstract][Full Text] [Related]
15. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
16. Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.
Radomski TR; Huang Y; Park SY; Sileanu FE; Thorpe CT; Thorpe JM; Fine MJ; Gellad WF
J Am Geriatr Soc; 2019 Sep; 67(9):1922-1927. PubMed ID: 31276198
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Hospital Resource Use and Outcomes Among Hospitalists, Primary Care Physicians, and Other Generalists.
Stevens JP; Nyweide DJ; Maresh S; Hatfield LA; Howell MD; Landon BE
JAMA Intern Med; 2017 Dec; 177(12):1781-1787. PubMed ID: 29131897
[TBL] [Abstract][Full Text] [Related]
18. Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.
Shahangian S; Fan L; Sharma KP; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1352. PubMed ID: 33932150
[TBL] [Abstract][Full Text] [Related]
19. Are there regional tendencies toward controversial screening practices? A study of prostate and breast cancer screening in a Medicare population.
Raffin E; Onega T; Bynum J; Austin A; Carmichael D; Bronner K; Goodney P; Hyams ES
Cancer Epidemiol; 2017 Oct; 50(Pt A):68-75. PubMed ID: 28822325
[TBL] [Abstract][Full Text] [Related]
20. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
